Browse CD96

Summary
SymbolCD96
NameCD96 molecule
Aliases TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location3p13-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain -
Function

May be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. May function at a time after T and NK cells have penetrated the endothelium using integrins and selectins, when they are actively engaging diseased cells and moving within areas of inflammation.

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0002228 natural killer cell mediated immunity
GO:0002237 response to molecule of bacterial origin
GO:0002367 cytokine production involved in immune response
GO:0002370 natural killer cell cytokine production
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002532 production of molecular mediator involved in inflammatory response
GO:0002534 cytokine production involved in inflammatory response
GO:0002683 negative regulation of immune system process
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002701 negative regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002707 negative regulation of lymphocyte mediated immunity
GO:0002715 regulation of natural killer cell mediated immunity
GO:0002716 negative regulation of natural killer cell mediated immunity
GO:0002718 regulation of cytokine production involved in immune response
GO:0002719 negative regulation of cytokine production involved in immune response
GO:0002727 regulation of natural killer cell cytokine production
GO:0002728 negative regulation of natural killer cell cytokine production
GO:0007160 cell-matrix adhesion
GO:0031348 negative regulation of defense response
GO:0031589 cell-substrate adhesion
GO:0032496 response to lipopolysaccharide
GO:0032609 interferon-gamma production
GO:0032649 regulation of interferon-gamma production
GO:0032689 negative regulation of interferon-gamma production
GO:0045088 regulation of innate immune response
GO:0045824 negative regulation of innate immune response
GO:0050777 negative regulation of immune response
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Summary
SymbolCD96
NameCD96 molecule
Aliases TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location3p13-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CD96 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CD96 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26787820Lung CarcinomaInhibit immunity (NK cell function)Blocking CD96 in Tigit(-/-)mice significantly reduced experimental and spontaneous metastases compared with its activity in wild-type mice.
Summary
SymbolCD96
NameCD96 molecule
Aliases TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location3p13-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CD96 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCD96
NameCD96 molecule
Aliases TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location3p13-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CD96 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.170.643
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0780.914
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.350.545
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0830.821
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3620.754
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6460.653
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.2510.0605
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15112.0480.0699
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4080.738
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.960.0883
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.7020.331
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0480.788
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CD96 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59400400.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCD96
NameCD96 molecule
Aliases TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location3p13-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CD96. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCD96
NameCD96 molecule
Aliases TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location3p13-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CD96. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CD96.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCD96
NameCD96 molecule
Aliases TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location3p13-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CD96. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCD96
NameCD96 molecule
Aliases TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location3p13-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CD96 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCD96
NameCD96 molecule
Aliases TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location3p13-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CD96 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCD96
NameCD96 molecule
Aliases TACTILE; CD96 antigen; T cell activation, increased late expression; cell surface antigen CD96; t cell-activ ......
Chromosomal Location3p13-q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CD96 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.